Anticancer Agents Derived from Cyclic Thiosulfonates: Structure‐Reactivity and Structure‐Activity Relationships

Reported are structure‐property‐function relationships associated with a class of cyclic thiosulfonate molecules—disulfide‐bond disrupting agents (DDAs)—with the ability to downregulate the Epidermal Growth Factor Receptor (HER) family in parallel and selectively induce apoptosis of EGFR+ or HER2+ b...

Full description

Saved in:
Bibliographic Details
Published in:ChemMedChem 2022-07, Vol.17 (14), p.e202200165-n/a
Main Authors: Ghilardi, Amanda F., Yaaghubi, Elham, Ferreira, Renan B., Law, Mary E., Yang, Yinuo, Davis, Bradley J., Schilson, Christopher M., Ghiviriga, Ion, Roitberg, Adrian E., Law, Brian K., Castellano, Ronald K.
Format: Article
Language:English
Subjects:
Anticancer
Anticancer properties
Antineoplastic Agents - pharmacology
Antitumor activity
Antitumor agents
Apoptosis
Breast cancer
Chemical bonds
Cyclic thiosulfonate
Cysteine
Epidermal growth factor
ErbB-2 protein
Growth factors
Lead compounds
Optimization
Protein disulfide isomerase inhibitors
Protein disulfide-isomerase
Protein Disulfide-Isomerases
Structure-Activity Relationship
Structure-function relationships
Sulfhydryl Compounds - chemistry
Thiol reactivity
Thiosulfonate
Tunable ring opening
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reported are structure‐property‐function relationships associated with a class of cyclic thiosulfonate molecules—disulfide‐bond disrupting agents (DDAs)—with the ability to downregulate the Epidermal Growth Factor Receptor (HER) family in parallel and selectively induce apoptosis of EGFR+ or HER2+ breast cancer cells. Recent findings have revealed that the DDA mechanism of action involves covalent binding to the thiol(ate) from the active site cysteine residue of members of the protein disulfide isomerase (PDI) family. Reported is how structural modifications to the pharmacophore can alter the anticancer activity of cyclic thiosulfonates by tuning the dynamics of thiol‐thiosulfonate exchange reactions, and the studies reveal a correlation between the biological potency and thiol‐reactivity. Specificity of the cyclic thiosulfonate ring‐opening reaction by a nucleophilic attack can be modulated by substituent addition to a parent scaffold. Lead compound optimization efforts are also reported, and have resulted in a considerable decrease of the IC50/IC90 values toward HER‐family overexpressing breast cancer cells. Exchange dynamics: Reported are structure‐property‐function relationships of cyclic thiosulfonate molecules—disulfide‐bond disrupting agents (DDAs)—that downregulate the Epidermal Growth Factor Receptor (HER) family in parallel and selectively induce apoptosis of EGFR+ or HER2+ breast cancer cells. Shown recently, the DDAs covalently bind to the active site cysteine residue(s) of selected protein disulfide isomerases (PDIs). Shown here, structural modifications to the DDAs can tune the dynamics of thiol‐thiosulfonate exchange reactions and lead to more potent compounds.
ISSN:1860-7179
1860-7187
1860-7187
DOI:10.1002/cmdc.202200165